John Welch, M.D., Ph.D.
Interim Chief Medical Officer
John Welch, M.D., Ph.D. oversees A2 Bio’s clinical programs, developing novel cell therapy. John is a physician-scientist committed to integrating basic science and clinical medicine to improve the diagnosis and treatment of cancers.
John joined A2 Bio in 2022 to lead first-in-human, first-in-class Tmod clinical trials. This has been an exciting opportunity to clinically adapt novel cell therapy designs that mitigate on-target/off-tumor toxicity by leveraging tumor genomic characteristics.
Before joining A2 Bio, John was faculty at Washington University in St. Louis, where his group integrated early genomics into clinical trials. His group first mapped the subclonal patterns of somatic mutations in AML/MDS, identified recurrent cohesin mutations, identified decitabine responses in TP53-mutated patients, and demonstrated that serial exome sequencing could quantify molecular responses in both bone marrow and blood.
John received his Bachelor’s degree from Brigham Young University, MD/PhD from the University of California at San Diego, completed an Oncology fellowship at Washington University in St. Louis, and has been elected to the American Society for Clinical Investigation.